6 new oncology trials approved in Europe
 |
Oncology Hero |
6 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week.
Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high
| Sponsor: UZ Brussel | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestRandomized study evaluating the impact of an innovative and cooperative pathway integrating OncoGeriatric, pharmaceutical and Pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy. (POG)
| Sponsor: Institut Gustave Roussy | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
| Sponsor: Amgen Inc. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
| Sponsor: Bristol-Myers Squibb Services Unlimited Company | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestZoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma (ZAPGIO)
| Sponsor: Region Nordjylland | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestRandomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
| Sponsor: Ribocure Pharmaceuticals AB | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 10 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study MeetURO and FICOG trial Sponsor: Fondazione IRCCS Istituto Nazionale Dei Tumori Phase: 3 Interested in offering this trial to suitable patients?...
In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...
Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...